Gene Technologies have submitted to the Food and Drug Administration
a 1,000-page report that may contain an HIV/AIDS cure.
company publicized it had turned in an application for an
Investigational New Drug to the FDA for the AGT’s lead HIV program.
This program, called AGT 103T, is a cell and gene therapy program
unlike anything else available.
are roughly 1.1 million people living with HIV/AIDS in the U.S.
HIV was discovered in the late 20th
century, there are still a limited number of antiretroviral drugs
that can restore a person’s quality of life. And, even though there
have been significant medical advancements, there is still no cure
key behind a single-dose drug is to get rid of HIV altogether,
allowing those infected to live once more.
Clinical Development & Regulatory Affairs Vice President Irene
Tennant said things were done with a purpose in mind. The goal was to
improve people’s lives, reduce their suffering and boost their
Galvin, American Gene Technologies CEO, said the key is to get people
out of their medical jail and return them to life. Galvin said the
move is very important – to ensure permanent immunity, which is
something they feel the project can do.
a huge task to undertake, and the county leadership, investors and
others have helped with the effort. He said everybody involved
should take credit for bringing all the elements together.
The FDA is likely to respond to the AGT report. If approved, they can start the phase one clinical trial in January.